Bravecto

Fluralaner, the active ingredient in Bravecto, is an Isoxazoline presented as a chewable tablet for oral use. It treats and prevents flea and tick infestations in dogs and cats. GNH USA supplies Bravecto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Bravecto is an ectoparasiticide used to control flea and tick infestations in companion animals.

- Flea infestation: eliminates existing fleas and prevents new infestations in dogs and cats. - Tick infestation (Ixodes ricinus, Rhipicephalus sanguineus, Dermacentor variabilis): kills attached ticks and helps prevent tick‑borne diseases in dogs.

Adverse reactions to Bravecto are generally uncommon but can occur.

Common Side Effects: - Vomiting: occasional mild to moderate episodes. - Diarrhea: transient loose stools. - Decreased appetite: reduced food intake. - Lethargy: mild temporary fatigue. - Skin irritation: localized pruritus or redness.

Serious or Rare Side Effects: - Seizures: rare neurologic events, especially in predisposed animals. - Severe allergic reaction: anaphylaxis with facial swelling or difficulty breathing. - Hepatic abnormalities: elevated liver enzymes in isolated cases. - Severe skin reactions: extensive dermatitis or ulceration.

When using Bravecto, consider the following safety measures.

- Pregnancy and lactation: safety not established; consult a veterinarian before use. - Age restrictions: not recommended for puppies under eight weeks of age. - Weight considerations: dosage is weight‑based; ensure accurate weight measurement. - Hypersensitivity: avoid in animals with known allergy to isoxazolines. - Concurrent illness: use caution in animals with a history of seizures. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Bravecto may interact with other medications; monitor accordingly.

Major Interactions (Avoid): - Co‑administration with other isoxazoline ectoparasiticides: risk of additive neurotoxicity. - Use with seizure‑lowering drugs (e.g., phenobarbital): may increase seizure risk.

Moderate Interactions (Monitor Closely): - Concurrent glucocorticoids: observe for gastrointestinal upset. - Other oral medications: monitor for potential absorption changes. - Antifungal agents: watch for altered plasma levels of fluralaner.